文献速递其他结缔组织病

尼达尼布对局限性皮肤型系统性硬化症合并间质性肺病患者的影响

Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

在SENSCIS试验中,277例局限性皮肤型系统性硬化症合并间质性肺病患者随机接受尼达尼布或安慰剂,52周内用力肺活量年下降率安慰剂组为-74.5 ml/年,尼达尼布组为-49.1 ml/年,差异为25.3 ml/年(95%CI -28.9, 79.6)。在SENSCIS-ON扩展研究中,183例患者52周内用力肺活量平均变化分别为-41.5 ml和-45.1 ml。结论认为尼达尼布通过靶向肺纤维化减缓此类患者的肺功能下降。

要点

  • SENSCIS试验中局限性皮肤型系统性硬化症合并间质性肺病患者52周用力肺活量年下降率尼达尼布组较安慰剂组减慢25.3 ml/年(95%CI -28.9, 79.6)。
  • SENSCIS-ON扩展研究中,先前安慰剂组转为尼达尼布者52周用力肺活量平均变化为-41.5 ml,先前尼达尼布组继续治疗者为-45.1 ml。
  • 作者结论认为局限性皮肤型系统性硬化症患者可能发生进展性纤维化性间质性肺病,尼达尼布可减缓其肺功能下降。

核心结论

  • 局限性皮肤型系统性硬化症患者可能发生进展性纤维化性间质性肺病;尼达尼布通过靶向肺纤维化减缓此类患者的肺功能下降。

研究设计与样本

  • SENSCIS试验将系统性硬化症相关间质性肺病患者随机分配接受尼达尼布或安慰剂治疗。
  • 完成SENSCIS试验的患者可进入SENSCIS-ON扩展研究,所有患者均接受开放标签尼达尼布治疗。

主要发现

  • 在SENSCIS试验中接受治疗的277例局限性皮肤型系统性硬化症患者中,52周内用力肺活量年下降率(标准误)安慰剂组为-74.5(19.2)ml/年,尼达尼布组为-49.1(19.8)ml/年,差异为25.3 ml/年(95%CI -28.9, 79.6)。
  • 在249例有第52周数据的患者中,第52周时用力肺活量平均变化(标准误)安慰剂组为-86.4(21.1)ml,尼达尼布组为-39.1(22.2)ml。
  • 在183例参与SENSCIS-ON且有第52周数据的局限性皮肤型系统性硬化症患者中,从基线至SENSCIS-ON第52周用力肺活量平均变化(标准误)在SENSCIS试验中接受安慰剂并于SENSCIS-ON中开始尼达尼布治疗的患者为-41.5(24.0)ml,在SENSCIS试验中接受尼达尼布并于SENSCIS-ON中继续治疗的患者为-45.1(19.1)ml。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomized to receive nintedanib or placebo. Patients who completed the SENSCIS trial were eligible to enter SENSCIS-ON, in which all patients received open-label nintedanib. RESULTS: Among 277 patients with lcSSc treated in the SENSCIS trial, the rate (s.e.) of decline in forced vital capacity (FVC; ml/year) over 52 weeks was -74.5 (19.2) in the placebo group and -49.1 (19.8) in the nintedanib group (difference: 25.3 [95% CI -28.9, 79.6]). Among 249 patients with data at week 52, mean (s.e.) change in FVC at week 52 was -86.4 (21.1) ml in the placebo group and -39.1 (22.2) ml in the nintedanib group. Among 183 patients with lcSSc who participated in SENSCIS-ON and had data at week 52, mean (s.e.) change in FVC from baseline to week 52 of SENSCIS-ON was -41.5 (24.0) ml in patients who took placebo in the SENSCIS trial and initiated nintedanib in SENSCIS-ON and -45.1 (19.1) ml in patients who took nintedanib in the SENSCIS trial and continued it in SENSCIS-ON. CONCLUSION: Patients with lcSSc may develop progressive fibrosing ILD. By targeting pulmonary fibrosis, nintedanib slows decline in lung function in patients with lcSSc and ILD. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT02597933 and NCT03313180.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Allanore Y, Khanna D, Smith V, et al. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology (Oxford). 2024. PMID: 37294870. doi:10.1093/rheumatology/kead280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。